Semaglutide
Once-weekly metabolic control.
A long-acting GLP-1 receptor agonist for adults pursuing improved glycemic control and meaningful weight reduction under physician supervision. 0.5 1.0 1.5 2.0 2.5 2.
GLP-1 biology, engineered.
A synthetic peptide that mimics the body's GLP-1 — stimulating insulin secretion, suppressing glucagon, and slowing gastric emptying with once-weekly dosing.
- Adults pursuing meaningful weight reduction
- Patients with type 2 diabetes seeking better glycemic control
- Anyone exploring once-weekly metabolic therapy
Improved Glycemic Control
Glucose-dependent insulin secretion lowers HbA1c and meal spikes. Blood sugar smooths out, post-meal spikes ease.
Clinically Significant Weight Loss
Acts on hunger and satiety pathways to reduce appetite. Hunger quiets and portion size feels natural.
Cardiovascular Risk Reduction
Clinical trials report reduced major cardiovascular events in T2D. Important risk markers may shift favorably.
Once-Weekly Adherence
A single weekly injection improves consistency over daily dosing. One weekly injection — easy to keep consistent.
Broad Therapeutic Reach
Under investigation for additional metabolic and neurodegenerative use. Active research expanding to adjacent conditions.
Reduced hunger emerges; initial GI adjustment
Weight loss accelerates; eating patterns settle.
Sustained results; metabolic profile improves.
- Physician-supervised by Thomas Nabity, MD
- 503A / 503B compounding pharmacy sourcing
- Pre-protocol labs, body composition, and review
- 30 / 60 / 90-day follow-up with companion support